{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:39:24Z","timestamp":1787697564827,"version":"build-2784847793"},"reference-count":220,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116342","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T01:05:43Z","timestamp":1710637543000},"page":"116342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Glucagon-like peptide-1 analogs: Miracle drugs are blooming?"],"prefix":"10.1016","volume":"269","author":[{"given":"Binbin","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-105X","authenticated-orcid":false,"given":"Lidan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116342_bib1","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/s41591-023-02538-7","article-title":"A revolution in obesity treatment","volume":"29","author":"Lingvay","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib2","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","article-title":"Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency","volume":"16","author":"Alavi","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116342_bib3","first-page":"2580","article-title":"Research progress of glucagon-like receptor agonists","volume":"29","author":"Cheng","year":"2020","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1016\/j.ejmech.2024.116342_bib4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.diabres.2011.12.015","article-title":"An overview of the pharmacokinetics, efficacy and safety of liraglutide","volume":"97","author":"Bode","year":"2012","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2024.116342_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.diabet.2019.01.006","article-title":"Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings","volume":"45","author":"Guerci","year":"2019","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications","volume":"58","author":"Manandhar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.diabet.2017.10.007","article-title":"Durability of protective effect of dulaglutide on pancreatic beta-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure","volume":"44","author":"Kimura","year":"2018","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jdiacomp.2018.12.013","article-title":"Liraglutide prevents beta-cell apoptosis via inactivation of NOX2 and its related signaling pathway","volume":"33","author":"Ding","year":"2019","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.ejmech.2024.116342_bib10","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/jcmm.13259","article-title":"Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic beta-cell apoptosis","volume":"22","author":"Kapodistria","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ejmech.2024.116342_bib12","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1463-1326.2008.00853.x","article-title":"GLP-1: physiological effects and potential therapeutic applications","volume":"10","author":"Aaboe","year":"2008","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejmech.2024.116342_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.peptides.2017.12.009","article-title":"Newer GLP-1 receptor agonists and obesity-diabetes","volume":"100","author":"Brown","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmstadter","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2024.116342_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3132\/dvdr.2004.005","article-title":"Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure","volume":"1","author":"Thrainsdottir","year":"2004","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ejmech.2024.116342_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ejmech.2024.116342_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","article-title":"Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients","volume":"20","author":"Saraiva","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2024.116342_bib20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.rgmx.2019.05.004","article-title":"Extrahepatic complications of non-alcoholic fatty liver disease: its impact beyond the liver","volume":"84","author":"Velarde-Ruiz Velasco","year":"2019","journal-title":"Rev. Gastroenterol. M\u00e9xico"},{"key":"10.1016\/j.ejmech.2024.116342_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.lpm.2019.09.015","article-title":"[Pharmacological treatment of NASH]","volume":"48","author":"Serfaty","year":"2019","journal-title":"Presse Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-19-0007","article-title":"Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis","volume":"241","author":"Kalavalapalli","year":"2019","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib25","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2024.116342_bib27","article-title":"Liraglutide and its neuroprotective properties-focus on possible biochemical mechanisms in Alzheimer's disease and cerebral ischemic events","volume":"20","author":"Wicinski","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/10717544.2022.2036873","article-title":"Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2024.116342_bib30","first-page":"953","article-title":"Research progress on the relationship between glucagon-like peptide 1 and bone metabolism","volume":"34","author":"Lu","year":"2019","journal-title":"Clinical Focus"},{"key":"10.1016\/j.ejmech.2024.116342_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170481","article-title":"The glucagon-like peptide-1 (GLP-1) analog exenatide ameliorates intrauterine adhesions in mice","volume":"137","author":"Ma","year":"2021","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.domaniend.2016.10.005","article-title":"Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle","volume":"59","author":"ThanThan","year":"2017","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.mie.2019.02.008","article-title":"Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors","volume":"622","author":"Lear","year":"2019","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2024.116342_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1060028017689878","article-title":"Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management","volume":"51","author":"McCarty","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116342_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118966","article-title":"Beinaglutide shows significantly beneficial effects in diabetes\/obesity-induced nonalcoholic steatohepatitis in ob\/ob mouse model","volume":"270","author":"Fang","year":"2021","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116342_bib38","first-page":"559","article-title":"Research progress on glucagon-like peptide-1 receptor agonists on market","volume":"43","author":"Du Xiaoxiao","year":"2020","journal-title":"Drug Evaluation Research"},{"key":"10.1016\/j.ejmech.2024.116342_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1156521","article-title":"Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial","volume":"14","author":"Wen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103382","article-title":"Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2024.116342_bib41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/osp4.342","article-title":"Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study","volume":"5","author":"Zhang","year":"2019","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.ejmech.2024.116342_bib42","first-page":"421","article-title":"Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight\/obesity","volume":"65","author":"Wang","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.ejmech.2024.116342_bib43","article-title":"Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: a case report","volume":"100","author":"Ding","year":"2021","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejmech.2024.116342_bib44","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.1074\/jbc.270.17.10136","article-title":"Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro","volume":"270","author":"Rothenberg","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/10425170109024999","article-title":"cDNA cloning of proglucagon from the stomach and pancreas of the dog","volume":"12","author":"Irwin","year":"2001","journal-title":"DNA Sequence"},{"key":"10.1016\/j.ejmech.2024.116342_bib46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature22394","article-title":"Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116342_bib47","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib48","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1073\/pnas.94.15.7915","article-title":"The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties","volume":"94","author":"Irwin","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116342_bib49","first-page":"267","article-title":"J. Trout and chicken proglucagon: alternative splicing generates MRNA transcripts encoding glucagon-like peptide 2","volume":"9","author":"Irwin","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib50","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1016\/S0021-9258(19)40654-6","article-title":"Chicken glucagon. Isolation and amino acid sequence studies","volume":"250","author":"Pollock","year":"1975","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib51","doi-asserted-by":"crossref","first-page":"9746","DOI":"10.1016\/S0021-9258(19)81581-8","article-title":"Isolation of peptide hormones from the pancreas of the bullfrog (Rana catesbeiana). Amino acid sequences of pancreatic polypeptide, oxyntomodulin, and two glucagon-like peptides","volume":"263","author":"Pollock","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib52","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/endo-123-6-2639","article-title":"Pancreatic proglucagon processing: isolation and structures of glucagon and glucagon-like peptide from gene I. Endocrinology","volume":"123","author":"Nichols","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2024.116342_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0167-0115(86)90205-3","article-title":"Isolation and structures of coho salmon (Oncorhynchus kisutch) glucagon and glucagon-like peptide","volume":"14","author":"Plisetskaya","year":"1986","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejmech.2024.116342_bib54","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1074\/jbc.272.7.4108","article-title":"Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard","volume":"272","author":"Chen","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/gcen.1993.1109","article-title":"Primary structures of glucagon and glucagon-like peptide isolated from the intestine of the parasitic phase lamprey Petromyzon marinus","volume":"91","author":"Conlon","year":"1993","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0925-4773(99)00151-3","article-title":"Early appearance of pancreatic hormone-expressing cells in the zebrafish embryo","volume":"87","author":"Argenton","year":"1999","journal-title":"Mech. Dev."},{"key":"10.1016\/j.ejmech.2024.116342_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/srep37744","article-title":"Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions","volume":"6","author":"Tsend-Ayush","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116342_bib58","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/dom.12253","article-title":"Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus","volume":"16","author":"Bolli","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib59","first-page":"685","article-title":"Liraglutide: a glucagon-like peptide-1 agonist for chronic weight management, consult","volume":"31","author":"Manigault","year":"2016","journal-title":"Pharm. Times"},{"key":"10.1016\/j.ejmech.2024.116342_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib61","first-page":"19","article-title":"Exenatide once weekly for management of type 2 diabetes: a review","volume":"14","author":"Inaishi","year":"2022","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116342_bib62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/dom.12084","article-title":"Once weekly exenatide: efficacy, tolerability and place in therapy","volume":"15","author":"Wysham","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib63","article-title":"GLP-1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib64","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/17425255.2015.1068288","article-title":"Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics\/pharmacodynamics and clinical efficacy","volume":"11","author":"Br\u00f8nden","year":"2015","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.116342_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3810\/pgm.2014.11.2836","article-title":"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist","volume":"126","author":"Young","year":"2014","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40262-016-0499-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of albiglutide","volume":"56","author":"Bronden","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116342_bib67","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.2337\/dc19-2316","article-title":"Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial","volume":"43","author":"Rosenstock","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2024.116342_bib68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib69","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/2042098616667352","article-title":"Albiglutide-induced pancreatitis","volume":"7","author":"Jain","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ejmech.2024.116342_bib70","first-page":"22","article-title":"Research progress on type 2 diabetes drug dulaglutide","volume":"16","author":"Fang","year":"2018","journal-title":"Clinical Medication Journal"},{"key":"10.1016\/j.ejmech.2024.116342_bib71","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2147\/DMSO.S34418","article-title":"A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide","volume":"8","author":"Gurung","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ejmech.2024.116342_bib72","first-page":"1327","article-title":"Studies on glucagon like peptide-1 (GLP-1) analogues: a review","volume":"34","author":"Jiang","year":"2020","journal-title":"J. Chem. Eng. Chin. Univ."},{"key":"10.1016\/j.ejmech.2024.116342_bib73","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2024.116342_bib74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/17512433.2016.1141046","article-title":"Dulaglutide (LY-2189265) for the treatment of type 2 diabetes","volume":"9","author":"Scheen","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116342_bib75","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116342_bib76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/asj\/sjad211","article-title":"Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: a google trends analysis","volume":"44","author":"Han","year":"2023","journal-title":"Aesthetic Surg. J."},{"key":"10.1016\/j.ejmech.2024.116342_bib77","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist","volume":"57","author":"Hall","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116342_bib78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib79","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cmdc.201600374","article-title":"Half-life extension of biopharmaceuticals using chemical methods: alternatives to PEGylation","volume":"11","author":"van Witteloostuijn","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116342_bib80","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/bcp.14091","article-title":"Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: a pharmacokinetic study","volume":"85","author":"Wang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116342_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1106868","article-title":"Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: an open-label, parallel-arm, randomized, metformin-controlled trial","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib82","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/dom.14198","article-title":"Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: a multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial","volume":"23","author":"Shuai","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13340-019-00423-8","article-title":"The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Diabetol Int"},{"key":"10.1016\/j.ejmech.2024.116342_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist","volume":"22","author":"Bucheit","year":"2020","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116342_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2024.116342_bib86","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.addr.2016.10.005","article-title":"Oral delivery of peptides: opportunities and issues for translation","volume":"106","author":"Brayden","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2024.116342_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12951-020-00619-0","article-title":"Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and beta-cell repair of type 2 diabetes mice","volume":"18","author":"Bao","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2024.116342_bib88","article-title":"Construction and evaluation of chitosan-based nanoparticles for oral administration of exenatide in type 2 diabetic rats","volume":"14","author":"Yang","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.ejmech.2024.116342_bib89","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2018.12.028","article-title":"Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model","volume":"294","author":"Suzuki","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2024.116342_bib90","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.xphs.2018.04.011","article-title":"Bioadhesive chitosan-coated cationic nanoliposomes with improved insulin encapsulation and prolonged oral hypoglycemic effect in diabetic mice","volume":"107","author":"Shalaby","year":"2018","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801123","article-title":"Protein corona liposomes achieve efficient oral insulin delivery by overcoming mucus and epithelial barriers","volume":"8","author":"Wang","year":"2019","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2024.116342_bib92","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.7150\/thno.61747","article-title":"Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116342_bib93","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules","volume":"32","author":"Choonara","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejmech.2024.116342_bib94","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.xphs.2017.12.012","article-title":"Bile acid as an effective absorption enhancer for oral delivery of epidermal growth factor receptor-targeted hybrid peptide","volume":"107","author":"Gaowa","year":"2018","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113925","article-title":"Formulation strategies to improve the efficacy of intestinal permeation enhancers","volume":"177","author":"Maher","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2024.116342_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122131","article-title":"Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: sodium caprate (C10) and salcaprozate sodium (SNAC)","volume":"626","author":"Twarog","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2024.116342_bib97","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpharm.2018.05.055","article-title":"The use of low molecular weight protamine to enhance oral absorption of exenatide","volume":"547","author":"Zhang","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2024.116342_bib98","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib99","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.ejmech.2024.116342_bib100","author":"Company"},{"key":"10.1016\/j.ejmech.2024.116342_bib101","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib102","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib103","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1016\/S0021-9258(17)37366-0","article-title":"Structure-activity studies of glucagon-like peptide-1","volume":"269","author":"Adelhorst","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib104","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/dmrr.553","article-title":"Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes","volume":"21","author":"Hui","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ejmech.2024.116342_bib105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ejmech.2016.10.044","article-title":"Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling","volume":"127","author":"Plisson","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib106","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a dual GLP-1R\/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2024.116342_bib107","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1021\/ja504390x","article-title":"Therapeutic protein-polymer conjugates: advancing beyond PEGylation","volume":"136","author":"Pelegri-O'Day","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116342_bib108","first-page":"377","article-title":"Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1, Bioconjug","volume":"16","author":"Lee","year":"2005","journal-title":"Chem"},{"key":"10.1016\/j.ejmech.2024.116342_bib109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.regpep.2008.09.008","article-title":"Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent","volume":"152","author":"Lee","year":"2009","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejmech.2024.116342_bib110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jphs.2018.08.009","article-title":"C-terminal site-specific PEGylated Exendin-4 analog: a long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db\/db mice","volume":"138","author":"Tang","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117752","article-title":"Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies","volume":"254","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2017.03.032","article-title":"Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents","volume":"132","author":"Han","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114672","article-title":"Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: an application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects","volume":"242","author":"Lin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib114","first-page":"651","article-title":"Advances in research on modification of protein and peptide drugs with fatty acids","volume":"39","author":"Wang","year":"2015","journal-title":"Progress in Pharmaceutical Sciences"},{"key":"10.1016\/j.ejmech.2024.116342_bib115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejps.2018.07.032","article-title":"Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity","volume":"123","author":"Han","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24040779","article-title":"Novel site-specific fatty chain-modified GLP-1 receptor agonist with potent antidiabetic effects","volume":"24","author":"Zhong","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116342_bib117","series-title":"Preparation of Glycosylated GLP-1 Peptide","first-page":"126","author":"Kajihara","year":"2009"},{"key":"10.1016\/j.ejmech.2024.116342_bib118","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1016\/j.bmcl.2010.06.002","article-title":"Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution","volume":"20","author":"Ueda","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116342_bib119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/acs.molpharmaceut.6b00787","article-title":"Neoglycolipids for prolonging the effects of peptides: self-assembling glucagon-like peptide 1 analogues with albumin binding properties and potent in vivo efficacy","volume":"14","author":"van Witteloostuijn","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116342_bib120","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1021\/acsomega.8b00467","article-title":"Glycosaminoglycan conjugation for improving the duration of therapeutic action of glucagon-like peptide-1","volume":"3","author":"Ichikawa","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116342_bib121","first-page":"74","article-title":"Development and present situation of long-acting glucagon-like peptide-1 agonists","volume":"45","author":"Bei","year":"2017","journal-title":"Prog in Microbiol Immunol"},{"key":"10.1016\/j.ejmech.2024.116342_bib122","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/dom.12602","article-title":"Once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once\u2010daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study","volume":"18","author":"Odawara","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib123","series-title":"Tianjin Institute of Pharmaceutical Research","first-page":"37pp","article-title":"Preparation and application of fusion protein containing GLP-1","author":"Gong","year":"2012"},{"key":"10.1016\/j.ejmech.2024.116342_bib124","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1021\/acs.biochem.7b00492","article-title":"Glucagon-like peptide 1 conjugated to recombinant human serum albumin variants with modified neonatal Fc receptor binding properties. Impact on molecular structure and half-life","volume":"56","author":"Bukrinski","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2024.116342_bib125","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s10989-019-09991-4","article-title":"Novel modified GLP-1 derivatives with prolonged glucose-lowering ability in vivo","volume":"26","author":"Liu","year":"2019","journal-title":"Int. J. Pept. Res. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116342_bib126","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1021\/acs.molpharmaceut.0c00995","article-title":"Stapled, long-acting Xenopus GLP-1-based dual GLP-1\/glucagon receptor agonists with potent therapeutic efficacy for metabolic disease","volume":"18","author":"Han","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116342_bib127","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/acschembio.0c00308","article-title":"Hydrocarbon-stitched peptide agonists of glucagon-like peptide-1 receptor","volume":"15","author":"Bird","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116342_bib128","doi-asserted-by":"crossref","first-page":"12595","DOI":"10.1021\/acs.jmedchem.0c00736","article-title":"Stapled and Xenopus glucagon-like peptide 1 (GLP-1)-Based dual GLP-1\/gastrin receptor agonists with improved metabolic benefits in rodent models of obesity and diabetes","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib129","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.jmedchem.1c00032","article-title":"Exendin 4-hapten conjugate capable of binding with endogenous antibodies for peptide half-life extension and exerting long-acting hypoglycemic activity","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2015.08.046","article-title":"Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists","volume":"103","author":"Swedberg","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib131","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib132","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ejmech.2024.116342_bib133","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2337\/db14-0440","article-title":"Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes","volume":"64","author":"Christensen","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2024.116342_bib134","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108332","article-title":"Tirzepatide: a novel, first-in-class, dual GIP\/GLP-1 receptor agonist","volume":"36","author":"Tall Bull","year":"2022","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.ejmech.2024.116342_bib136","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2024.116342_bib137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib138","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-021-01012-2","article-title":"Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"60","author":"Urva","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116342_bib139","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","article-title":"Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"61","author":"Urva","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116342_bib140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2024.116342_bib141","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib142","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116342_bib143","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2024.116342_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejmech.2024.116342_bib145","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/dom.13024","article-title":"Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus","volume":"19","author":"Schmitt","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib146","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.9b00835","article-title":"Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors","volume":"63","author":"Suzuki","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib147","author":"Therapeutics"},{"key":"10.1016\/j.ejmech.2024.116342_bib148","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF02427284","article-title":"Direct metabolic effects of gastric inhibitory polypeptide (GIP): dissociation at physiological levels of effects on insulin-stimulated fatty acid and glucose incorporation in rat adipose tissue","volume":"29","author":"Beck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2024.116342_bib149","first-page":"578","article-title":"Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase?","volume":"49","author":"Murphy","year":"1995","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.ejmech.2024.116342_bib150","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejmech.2024.116342_bib151","series-title":"AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116342_bib152","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cmet.2020.02.014","article-title":"Leveraging the gut to treat metabolic disease","volume":"31","author":"Gimeno","year":"2020","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib153","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170955","article-title":"Emerging roles of oxyntomodulin-based glucagon-like peptide-1\/glucagon co-agonist analogs in diabetes and obesity","volume":"162","author":"Zhihong","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40262-021-01094-y","article-title":"Population pharmacokinetics of cotadutide in subjects with type 2 diabetes","volume":"61","author":"Guan","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116342_bib156","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib157","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1038\/s41467-022-31328-x","article-title":"A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116342_bib158","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2024.116342_bib159","series-title":"Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA","year":"2024"},{"key":"10.1016\/j.ejmech.2024.116342_bib160","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1021\/acs.jmedchem.1c01456","article-title":"The design and optimization of monomeric multitarget peptides for the treatment of multifactorial diseases","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib161","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib162","series-title":"Use of a Long Acting GLP-1\/glucagon Receptor Dual Agonist for the Treatment of Non-alcoholic Fatty Liver Disease","first-page":"28","author":"Hwang","year":"2016"},{"key":"10.1016\/j.ejmech.2024.116342_bib163","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116342_bib164","first-page":"113","article-title":"Design and characterization of a surfactant\u2010conjugated, long\u2010acting, balanced GLP\u20101\/glucagon receptor dual agonist","author":"Nestor","year":"2021","journal-title":"Peptide Science"},{"key":"10.1016\/j.ejmech.2024.116342_bib165","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116342_bib166","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.apsb.2021.12.016","article-title":"Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis","volume":"12","author":"Song","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116342_bib167","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2024.116342_bib168","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cphy.c170055","article-title":"Glucagon-like peptide-2 and the regulation of intestinal growth and function","volume":"8","author":"Brubaker","year":"2018","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejmech.2024.116342_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2015.07.025","article-title":"The protective and anti-inflammatory effects of glucagon-like peptide-2 in an experimental rat model of necrotizing enterocolitis","volume":"75","author":"Nakame","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/nyas.14791","article-title":"The dual GLP-1 and GLP-2 receptor agonist Dapiglutide promotes barrier function in murine short bowel","volume":"1514","author":"Reiner","year":"2022","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib171","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.physbeh.2018.03.004","article-title":"Novel GLP-1\/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice","volume":"192","author":"Wismann","year":"2018","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejmech.2024.116342_bib172","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.tem.2017.04.005","article-title":"The role of PYY in pancreatic islet physiology and surgical control of diabetes","volume":"28","author":"Guida","year":"2017","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib173","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.peptides.2013.05.005","article-title":"PYY(3-36) into the arcuate nucleus inhibits food deprivation-induced increases in food hoarding and intake","volume":"47","author":"Teubner","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib174","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.ijo.0802696","article-title":"Effects of PYY [3-36] in rodent models of diabetes and obesity","volume":"28","author":"Pittner","year":"2004","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.ejmech.2024.116342_bib175","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cmet.2019.01.017","article-title":"A long-acting PYY3-36 analog mediates robust anorectic efficacy with minimal emesis in nonhuman primates","volume":"29","author":"Rangwala","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib176","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1021\/acs.jmedchem.0c01783","article-title":"Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis","volume":"64","author":"Milliken","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib177","doi-asserted-by":"crossref","first-page":"14201","DOI":"10.1021\/acs.jmedchem.2c01385","article-title":"Design of Xenopus GLP-1-based long-acting dual GLP-1\/Y(2) receptor agonists","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106808","article-title":"Evolution of peptide YY analogs for the management of type 2 diabetes and obesity","volume":"140","author":"Chen","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib179","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1210\/en.2011-0066","article-title":"Gastrin treatment stimulates beta-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats","volume":"152","author":"Tellez","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2024.116342_bib180","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1463-1326.2012.01676.x","article-title":"The novel GLP-1-gastrin dual agonist, ZP3022, increases \u03b2-cell mass and prevents diabetes in Db\/Db mice","volume":"15","author":"Fosgerau","year":"2013","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib181","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.peptides.2017.09.007","article-title":"Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes","volume":"100","author":"Pathak","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib182","first-page":"34","article-title":"Regulating satiety in bulimia nervosa: the role of cholecystokinin","volume":"48","author":"Hannon-Engel","year":"2012","journal-title":"Psychiatr. Care"},{"key":"10.1016\/j.ejmech.2024.116342_bib183","article-title":"Role of cholecystokinin and oxytocin in slower gastric emptying induced by physical exercise in rats","volume":"233","author":"Tolentino","year":"2021","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejmech.2024.116342_bib184","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.2337\/db15-0220","article-title":"A novel CCK-8\/GLP-1 hybrid peptide exhibiting prominent insulinotropic, glucose-lowering, and satiety actions with significant therapeutic potential in high-fat-fed mice","volume":"64","author":"Irwin","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2024.116342_bib185","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.appet.2018.05.131","article-title":"A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice","volume":"127","author":"Hornigold","year":"2018","journal-title":"Appetite"},{"key":"10.1016\/j.ejmech.2024.116342_bib186","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.peptides.2017.10.015","article-title":"A novel GLP-1\/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice","volume":"100","author":"Hasib","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2024.116342_bib187","doi-asserted-by":"crossref","DOI":"10.1177\/11795514211043868","article-title":"Xenin and related peptides: potential therapeutic role in diabetes and related metabolic disorders","volume":"14","author":"Craig","year":"2021","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.ejmech.2024.116342_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113723","article-title":"A GIP\/xenin hybrid in combination with exendin-4 improves metabolic status in db\/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice","volume":"171","author":"Craig","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116342_bib189","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211275","article-title":"A novel neurotensin\/xenin fusion peptide enhances beta-cell function and exhibits antidiabetic efficacy in high-fat fed mice","volume":"41","author":"Perry","year":"2021","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2024.116342_bib190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib191","article-title":"FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases","volume":"30","author":"Sonoda","year":"2017","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"key":"10.1016\/j.ejmech.2024.116342_bib192","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejmech.2024.116342_bib193","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116342_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2024.116342_bib195","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0168-8278(17)30295-7","article-title":"YH25724, a novel long-acting GLP-1\/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis","volume":"66","author":"Hong","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116342_bib196","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/d41591-023-00055-1","article-title":"Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib197","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metabol."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116342_bib198","first-page":"587","article-title":"Advances in multi\u2043receptor agonists based on gastrointestinal hormones in the treatment of diabetes and obesity","volume":"32","author":"Wang","year":"2023","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1016\/j.ejmech.2024.116342_bib199","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"I. Retatrutide phase 2 obesity trial, triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116342_bib200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib201","first-page":"64","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer's disease","author":"T","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2024.116342_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115036","article-title":"Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1\/glucagon\/Y(2) receptor triple agonist","volume":"247","author":"Yuan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib203","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1111\/bph.15860","article-title":"A GLP-1\/glucagon (GCG)\/CCK(2) receptors tri-agonist provides new therapy for obesity and diabetes","volume":"179","author":"Zhao","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116342_bib204","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejphar.2018.07.027","article-title":"Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4\/gastrin\/xenin-8-Gln","volume":"834","author":"Hasib","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116342_bib205","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3106","article-title":"Exendin-4(Lys(27) PAL)\/gastrin\/xenin-8-Gln: a novel acylated GLP-1\/gastrin\/xenin hybrid peptide that improves metabolic status in obese-diabetic (ob\/ob) mice","volume":"35","author":"Hasib","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ejmech.2024.116342_bib206","series-title":"Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116342_bib207","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2024.116342_bib208","series-title":"VK2735 for Weight Management Phase 2 (VENTURE)","author":"Viking Therapeutics","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116342_bib209","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acsptsci.8b00009","article-title":"Beyond glucagon-like peptide-1: is G-protein coupled receptor polypharmacology the path forward to treating metabolic diseases?","volume":"1","author":"Sloop","year":"2018","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2024.116342_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104492","article-title":"Discovery of a novel GLP-1\/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent","volume":"106","author":"Liu","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116342_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2024.116342_bib212","series-title":"Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116342_bib213","article-title":"Structural analysis of the dual agonism at GLP-1R and GCGR","volume":"120","author":"Li","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2024.116342_bib214","series-title":"Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People","year":"2020"},{"key":"10.1016\/j.ejmech.2024.116342_bib215","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.28962","article-title":"A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","volume":"65","author":"Valdecantos","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116342_bib216","series-title":"Research Study of a New Medicine (NNC9204-1706) in People with Overweight or Obesity","year":"2019"},{"key":"10.1016\/j.ejmech.2024.116342_bib217","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00125-013-2892-2","article-title":"A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice","volume":"56","author":"Bhat","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2024.116342_bib218","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib219","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz047","article-title":"Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist","volume":"105","author":"Parker","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116342_bib220","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat. Metab."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T01:33:08Z","timestamp":1712280788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":220,"alternative-id":["S0223523424002228"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116342","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 analogs: Miracle drugs are blooming?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116342"}}